drugset / Trial / NCT00445575
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
Phase 2/3
Completed
80 enrolled
French National Institute of Health and Medical Research
Charite University, Berlin, Germany · collabCliniques universitaires Saint-Luc- Université Catholique de Louvain · collabZonMw: The Netherlands Organisation for Health Research and Development · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This trial is intended to test the efficacy of an oral bisphosphonate (risedronate) to decrease bone pain and improve radiological aspect in fibrous dysplasia of bone.
Timeline
- Start
- 2007-07-22
- Primary completion
- 2017-12
- Completion
- 2017-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risedronate | Small molecule | 10 mg | Oral |
| Subject | Risedronate | Small molecule | 20 mg | Oral |
| Subject | Risedronate | Small molecule | 30 mg | Oral |